Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
Related Tickers: AQST
TL;DR
AQST filed an 8-K on 9/4/25, check for financial updates.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as MonoSol Rx, Inc., is incorporated in Delaware and headquartered in Warren, NJ.
Why It Matters
This filing indicates routine corporate reporting, including financial updates and exhibits, which are important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for corporate reporting and does not appear to contain material non-public information that would immediately impact risk.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- MonoSol Rx, Inc. (company) — Former company name
- September 4, 2025 (date) — Date of report
- Warren, NJ (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Aquestive Therapeutics, Inc.?
The primary purpose is to report under Regulation FD and to include financial statements and exhibits, as indicated by the filing details.
When was this 8-K filed?
The 8-K was filed on September 4, 2025.
What was Aquestive Therapeutics, Inc.'s former company name?
Aquestive Therapeutics, Inc.'s former company name was MonoSol Rx, Inc.
Where are Aquestive Therapeutics, Inc.'s principal executive offices located?
Aquestive Therapeutics, Inc.'s principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-09-04 07:11:06
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20250904.htm (8-K) — 27KB
- adcompressrelease-9x3x25.htm (EX-99.1) — 14KB
- adcompressrelease-9x3x25001.jpg (GRAPHIC) — 211KB
- adcompressrelease-9x3x25002.jpg (GRAPHIC) — 246KB
- adcompressrelease-9x3x25003.jpg (GRAPHIC) — 281KB
- adcompressrelease-9x3x25004.jpg (GRAPHIC) — 219KB
- 0001398733-25-000016.txt ( ) — 1479KB
- aqst-20250904.xsd (EX-101.SCH) — 2KB
- aqst-20250904_lab.xml (EX-101.LAB) — 21KB
- aqst-20250904_pre.xml (EX-101.PRE) — 12KB
- aqst-20250904_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On September 4, 2025, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing the U.S. Food and Drug Administration has informed the Company that an advisory committee meeting is not required for Anaphylm (dibutepinephrine) Sublingual Film. The Prescription Drug User Fee Act target action date for Anaphylm remains January 31, 2026. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report and incorporated in this Item 7.01 by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Press Release, dated September 4, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 4, 2025 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer